Ulf Fritz Bredeek Mendes, MD
Infectious Disease · Belmont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 2
- Since medical school
- 30 years
- Graduated 1996
Offices
2 locations · Dignity Health Medical Foundation · 1,211 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Sequoia Hospital. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mendes’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A31728 · Cancelled
Licence status: Cancelled · since 1977 · University of Zurich Faculty of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$74,943
Medicare paid this office $74,943 for 92 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $11,811 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $10,765 | $161 |
| Long return visit (40+ min) | 26 | $10,655 | $164 |
Who their Medicare patients are
92 Original Medicare patients in 2024. Average age 80 · Women 37% · Health risk score 2.85. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 57% · Diabetes 48% · Coronary heart disease 47% · Heart failure 43% · Atrial fibrillation 42% · Depression 35% · COPD 30% · Dementia 26% · Cancer 21% · Stroke 14%.
The office billed $191,847, Medicare allowed $95,145 and paid $74,943; for 2,387 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 92 | 2,387 | 80 | 2.85 | $191,847 | $74,943 |
| 2023 | 90 | 901 | 77 | 2.34 | $156,269 | $47,557 |
| 2022 | 104 | 741 | 79 | 2.18 | $148,383 | $41,863 |
| 2021 | 158 | 453 | 79 | 1.79 | $133,302 | $36,854 |
| 2020 | 16 | 90 | 71 | 1.31 | $21,850 | $9,015 |
| 2019 | 17 | 113 | 69 | 1.15 | $23,320 | $8,503 |
| 2018 | 16 | 114 | 68 | 0.96 | $22,835 | $7,481 |
| 2017 | 16 | 123 | 68 | 1.40 | $23,835 | $7,933 |
| 2016 | 19 | 129 | 67 | 0.93 | $27,240 | $9,998 |
| 2015 | 23 | 143 | 67 | 1.04 | $31,327 | $12,256 |
| 2014 | 23 | 139 | 65 | 1.03 | $23,434 | $11,737 |
| 2013 | 26 | 137 | 62 | 1.36 | $18,847 | $9,406 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $13,185 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $11,171 | $157 |
| Long return visit (40+ min) | 17 | $4,621 | $165 |
| Return visit (30+ min) | 19 | $4,370 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,148 | $72 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 76 | $16,906 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 71 | $8,277 | $113 |
| Return visit (30+ min) | 24 | $5,486 | $110 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $10,725 | $64 |
| Return visit (30+ min) | 25 | $5,884 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,697 | $121 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 32 | $3,301 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,662 | $92 |
| Short return visit (20+ min) | 15 | $1,282 | $85 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose | 44 | $920 | $21 |
2020: 1 service
| Return visit (30+ min) | 16 | $7,241 | $101 |
2019: 1 service
| Return visit (30+ min) | 17 | $6,361 | $88 |
2018: 1 service
| Return visit (30+ min) | 16 | $4,342 | $79 |
2017: 1 service
| Return visit (30+ min) | 15 | $5,480 | $78 |
2016: 2 services
| Return visit (30+ min) | 18 | $6,373 | $83 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,745 | $134 |
2015: 2 services
| Return visit (30+ min) | 20 | $8,580 | $91 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 11 | $1,507 | $137 |
2014: 2 services
| Return visit (30+ min) | 20 | $7,358 | $88 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $1,635 | $136 |
2013: 1 service
| Return visit (30+ min) | 24 | $7,678 | $83 |
Drugs they prescribed that Part D paid
$726,584
Pharmacies billed $726,584 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 384) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
230 generic and 154 brand-name prescriptions · $726,584 in drug cost · 21 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dovato | 56 | $255,150 | $4,556 |
| Rukobia | 14 | $146,428 | $10,459 |
| Tivicay | 27 | $102,512 | $3,797 |
| Juluca | 24 | $96,103 | $4,004 |
| Lamivudine | 13 | $1,125 | $87 |
See all 9 drugs
| Dovato | 56 | $255,150 | $4,556 |
| Rukobia | 14 | $146,428 | $10,459 |
| Tivicay | 27 | $102,512 | $3,797 |
| Juluca | 24 | $96,103 | $4,004 |
| Lamivudine | 13 | $1,125 | $87 |
| Atorvastatin | 34 | $398 | $12 |
| Finasteride | 14 | $378 | $27 |
| Lisinopril | 28 | $174 | $6 |
| Hydrochlorothiazide | 18 | $96 | $5 |
Year by year
| 2024 | 384 | 24 | 0% (0) | 40% | $726,584 |
| 2023 | 384 | 26 | None | 34% | $658,484 |
| 2022 | 438 | 27 | None | 34% | $510,756 |
| 2021 | 444 | 36 | None | 29% | $419,897 |
| 2020 | 886 | 25 | 0% (0) | None | $646,014 |
| 2019 | 898 | 24 | None | 33% | $660,923 |
| 2018 | 898 | 22 | None | 39% | $679,877 |
| 2017 | 972 | 23 | None | None | $785,029 |
| 2016 | 1,099 | 24 | None | 42% | $647,401 |
| 2015 | 1,022 | 26 | None | 41% | $598,355 |
| 2014 | 1,073 | 24 | None | 51% | $670,224 |
| 2013 | 1,146 | 30 | None | 54% | $632,504 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Dovato | 49 | $206,256 | $4,209 |
| Juluca | 38 | $137,390 | $3,616 |
| Tivicay | 17 | $79,371 | $4,669 |
| Lamivudine | 13 | $1,780 | $137 |
| Atorvastatin | 24 | $467 | $19 |
| Lisinopril | 23 | $356 | $15 |
| Finasteride | 16 | $288 | $18 |
| Ciclopirox | 11 | $243 | $22 |
| Nystatin | 14 | $186 | $13 |
| Simvastatin | 11 | $9 | $1 |
2022: 10 drugs
| Dovato | 44 | $168,982 | $3,841 |
| Juluca | 39 | $130,315 | $3,341 |
| Tivicay | 33 | $92,641 | $2,807 |
| Lamivudine | 24 | $4,357 | $182 |
| Testosterone | 11 | $3,944 | $359 |
| Atorvastatin | 27 | $474 | $18 |
| Finasteride | 16 | $419 | $26 |
| Lisinopril | 28 | $339 | $12 |
| Pravastatin | 11 | $335 | $30 |
| Nystatin | 11 | $241 | $22 |
2021: 13 drugs
| Dovato | 40 | $149,032 | $3,726 |
| Juluca | 43 | $142,011 | $3,303 |
| Tivicay | 20 | $39,069 | $1,953 |
| Efavirenz-Emtric-Tenofov Disop | 11 | $22,315 | $2,029 |
| Testosterone | 22 | $6,552 | $298 |
| Loteprednol Etabonate | 11 | $4,398 | $400 |
| Lamivudine | 19 | $2,000 | $105 |
| Atorvastatin | 33 | $687 | $21 |
| Ciclopirox | 11 | $284 | $26 |
| Nystatin | 13 | $283 | $22 |
| Finasteride | 13 | $251 | $19 |
| Lisinopril | 27 | $210 | $8 |
| Atenolol | 12 | $118 | $10 |
2020: 24 drugs
| Dovato | 61 | $220,128 | $3,609 |
| Juluca | 59 | $173,522 | $2,941 |
| Triumeq | 14 | $44,508 | $3,179 |
| Truvada | 11 | $20,392 | $1,854 |
| Testosterone | 31 | $11,970 | $386 |
| Nevirapine Er | 11 | $4,914 | $447 |
| Cialis | 11 | $4,138 | $376 |
| Valacyclovir | 30 | $2,685 | $90 |
| Creon | 11 | $1,703 | $155 |
| Atorvastatin | 72 | $1,143 | $16 |
| Finasteride | 29 | $689 | $24 |
| Zolpidem Tartrate Er | 11 | $415 | $38 |
| Tamsulosin | 15 | $415 | $28 |
| Omeprazole | 11 | $369 | $34 |
| Atenolol | 30 | $366 | $12 |
| Lisinopril | 63 | $360 | $6 |
| Gabapentin | 15 | $337 | $22 |
| Nystatin | 13 | $318 | $24 |
| Amlodipine Besylate | 46 | $269 | $6 |
| Levothyroxine | 21 | $230 | $11 |
| Hydrochlorothiazide | 37 | $110 | $3 |
| Metformin | 22 | $99 | $5 |
| Metoprolol | 14 | $51 | $4 |
| Simvastatin | 12 | $35 | $3 |
2019: 28 drugs
| Juluca | 75 | $204,588 | $2,728 |
| Triumeq | 38 | $134,795 | $3,547 |
| Dovato | 20 | $81,950 | $4,098 |
| Truvada | 21 | $37,744 | $1,797 |
| Atripla | 11 | $33,294 | $3,027 |
| Tivicay | 16 | $28,962 | $1,810 |
| Descovy | 13 | $23,608 | $1,816 |
| Testosterone | 29 | $15,611 | $538 |
| Nevirapine Er | 11 | $5,656 | $514 |
| Xarelto | 12 | $5,512 | $459 |
| Valacyclovir | 35 | $2,005 | $57 |
| Atorvastatin | 52 | $828 | $16 |
| Zolpidem Tartrate Er | 11 | $471 | $43 |
| Finasteride | 20 | $453 | $23 |
| Lisinopril | 58 | $381 | $7 |
| Dutasteride | 12 | $362 | $30 |
| Amlodipine Besylate | 50 | $306 | $6 |
| Levothyroxine | 23 | $269 | $12 |
| Buspirone | 12 | $268 | $22 |
| Atenolol | 24 | $180 | $7 |
| Hydrochlorothiazide | 51 | $179 | $4 |
| Warfarin | 24 | $151 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $138 | $13 |
| Gabapentin | 12 | $94 | $8 |
| Metformin | 19 | $51 | $3 |
| Simvastatin | 13 | $44 | $3 |
| Clopidogrel | 12 | $40 | $3 |
| Metoprolol | 12 | $35 | $3 |
2018: 29 drugs
| Triumeq | 53 | $212,680 | $4,013 |
| Juluca | 45 | $117,311 | $2,607 |
| Truvada | 43 | $74,345 | $1,729 |
| Androgel | 41 | $49,563 | $1,209 |
| Genvoya | 12 | $35,756 | $2,980 |
| Tivicay | 15 | $24,837 | $1,656 |
| Isentress | 12 | $19,022 | $1,585 |
| Nevirapine Er | 12 | $7,006 | $584 |
| Lyrica | 12 | $5,665 | $472 |
| Valacyclovir | 33 | $1,715 | $52 |
| Pravastatin | 15 | $658 | $44 |
| Atorvastatin | 36 | $550 | $15 |
| Zolpidem Tartrate Er | 13 | $361 | $28 |
| Buspirone | 13 | $345 | $27 |
| Levothyroxine | 25 | $343 | $14 |
| Finasteride | 15 | $326 | $22 |
| Omeprazole | 14 | $290 | $21 |
| Lisinopril | 57 | $277 | $5 |
| Amlodipine Besylate | 45 | $203 | $5 |
| Acyclovir | 14 | $156 | $11 |
| Zolpidem | 19 | $114 | $6 |
| Atenolol | 20 | $109 | $5 |
| Metformin | 15 | $99 | $7 |
| Hydrochlorothiazide | 29 | $98 | $3 |
| Metoprolol | 22 | $89 | $4 |
| Jantoven | 17 | $88 | $5 |
| Gabapentin | 13 | $79 | $6 |
| Clopidogrel | 13 | $41 | $3 |
| Simvastatin | 11 | $23 | $2 |
2017: 35 drugs
| Triumeq | 68 | $244,893 | $3,601 |
| Truvada | 63 | $102,337 | $1,624 |
| Genvoya | 24 | $66,735 | $2,781 |
| Androgel | 52 | $59,342 | $1,141 |
| Isentress | 23 | $33,595 | $1,461 |
| Atripla | 12 | $32,408 | $2,701 |
| Complera | 12 | $31,766 | $2,647 |
| Tivicay | 18 | $27,903 | $1,550 |
| Prezista | 12 | $18,634 | $1,553 |
| Intelence | 13 | $16,236 | $1,249 |
| Nevirapine Er | 12 | $7,020 | $585 |
| Norvir | 12 | $6,141 | $512 |
| Lyrica | 12 | $4,759 | $397 |
| Livalo | 12 | $3,053 | $254 |
| Valacyclovir | 32 | $1,565 | $49 |
| Pravastatin | 18 | $1,018 | $57 |
| Atorvastatin | 41 | $704 | $17 |
| Digox | 13 | $534 | $41 |
| Glipizide-Metformin | 13 | $526 | $40 |
| Acyclovir | 22 | $483 | $22 |
| Lisinopril | 81 | $460 | $6 |
| Omeprazole | 18 | $288 | $16 |
| Levothyroxine | 24 | $243 | $10 |
| Sulfamethoxazole-Trimethoprim | 15 | $227 | $15 |
| Doxazosin Mesylate | 12 | $211 | $18 |
| Amlodipine Besylate | 29 | $160 | $6 |
| Warfarin | 18 | $139 | $8 |
| Terazosin | 15 | $105 | $7 |
| Atenolol | 20 | $92 | $5 |
| Metoprolol | 19 | $82 | $4 |
| Metformin | 15 | $79 | $5 |
| Zolpidem | 11 | $72 | $7 |
| Clopidogrel | 12 | $59 | $5 |
| Simvastatin | 12 | $36 | $3 |
| Hydrochlorothiazide | 12 | $30 | $3 |
2016: 38 drugs
| Triumeq | 65 | $218,508 | $3,362 |
| Truvada | 68 | $100,454 | $1,477 |
| Tivicay | 35 | $49,796 | $1,423 |
| Androgel | 61 | $47,775 | $783 |
| Genvoya | 15 | $39,115 | $2,608 |
| Complera | 13 | $34,183 | $2,629 |
| Atripla | 12 | $28,596 | $2,383 |
| Isentress | 19 | $24,639 | $1,297 |
| Prezista | 12 | $16,189 | $1,349 |
| Epzicom | 11 | $14,396 | $1,309 |
| Intelence | 12 | $13,001 | $1,083 |
| Nevirapine Er | 13 | $7,609 | $585 |
| Norvir | 12 | $6,141 | $512 |
| Lyrica | 12 | $4,123 | $344 |
| Livalo | 18 | $3,897 | $217 |
| Valacyclovir | 32 | $969 | $30 |
| Atorvastatin | 49 | $674 | $14 |
| Pravastatin | 16 | $533 | $33 |
| Lisinopril | 101 | $532 | $5 |
| Sulfamethoxazole-Trimethoprim | 14 | $380 | $27 |
| Omeprazole | 26 | $367 | $14 |
| Acyclovir | 18 | $318 | $18 |
| Glipizide-Metformin | 12 | $309 | $26 |
| Levothyroxine | 25 | $231 | $9 |
| Warfarin | 26 | $207 | $8 |
| Doxazosin Mesylate | 12 | $196 | $16 |
| Amlodipine Besylate | 36 | $175 | $5 |
| Atenolol | 36 | $165 | $5 |
| Gemfibrozil | 12 | $148 | $12 |
| Metformin | 20 | $128 | $6 |
| Terazosin | 13 | $98 | $8 |
| Pantoprazole | 13 | $98 | $8 |
| Zolpidem | 15 | $91 | $6 |
| Allopurinol | 12 | $76 | $6 |
| Metoprolol | 12 | $40 | $3 |
| Clopidogrel | 12 | $39 | $3 |
| Simvastatin | 13 | $38 | $3 |
| Hydrochlorothiazide | 12 | $24 | $2 |
2015: 35 drugs
| Triumeq | 58 | $147,865 | $2,549 |
| Truvada | 69 | $93,439 | $1,354 |
| Tivicay | 38 | $50,332 | $1,325 |
| Isentress | 27 | $32,351 | $1,198 |
| Atripla | 12 | $25,902 | $2,158 |
| Complera | 11 | $24,293 | $2,208 |
| Androgel | 32 | $19,074 | $596 |
| Prezista | 15 | $18,891 | $1,259 |
| Epzicom | 13 | $15,638 | $1,203 |
| Selzentry | 12 | $14,248 | $1,187 |
| Intelence | 12 | $12,092 | $1,008 |
| Norvir | 22 | $8,521 | $387 |
| Nevirapine Er | 13 | $7,451 | $573 |
| Livalo | 18 | $3,350 | $186 |
| Lyrica | 11 | $3,318 | $302 |
| Valacyclovir | 24 | $1,646 | $69 |
| Atorvastatin | 39 | $755 | $19 |
| Lisinopril | 86 | $469 | $5 |
| Levothyroxine | 28 | $439 | $16 |
| Acyclovir | 25 | $404 | $16 |
| Cyclobenzaprine | 12 | $401 | $33 |
| Glyburide-Metformin | 12 | $225 | $19 |
| Doxazosin Mesylate | 12 | $217 | $18 |
| Amlodipine Besylate | 33 | $209 | $6 |
| Gabapentin | 13 | $195 | $15 |
| Gemfibrozil | 13 | $179 | $14 |
| Warfarin | 25 | $151 | $6 |
| Hydroxyzine | 11 | $136 | $12 |
| Metformin | 30 | $132 | $4 |
| Omeprazole | 13 | $128 | $10 |
| Atenolol | 34 | $119 | $3 |
| Terazosin | 17 | $98 | $6 |
| Pantoprazole | 13 | $98 | $8 |
| Allopurinol | 14 | $68 | $5 |
| Simvastatin | 16 | $57 | $4 |
2014: 32 drugs
| Truvada | 88 | $115,558 | $1,313 |
| Isentress | 66 | $86,421 | $1,309 |
| Tivicay | 53 | $73,228 | $1,382 |
| Prezista | 32 | $51,198 | $1,600 |
| Epzicom | 39 | $46,809 | $1,200 |
| Reyataz | 28 | $36,023 | $1,287 |
| Intelence | 28 | $30,457 | $1,088 |
| Atripla | 12 | $24,404 | $2,034 |
| Norvir | 62 | $23,163 | $374 |
| Androgel | 31 | $15,292 | $493 |
| Selzentry | 12 | $13,582 | $1,132 |
| Nevirapine Er | 13 | $6,829 | $525 |
| Lyrica | 13 | $3,776 | $290 |
| Livalo | 13 | $2,120 | $163 |
| Doxycycline Monohydrate | 11 | $749 | $68 |
| Pravastatin | 24 | $477 | $20 |
| Lisinopril | 80 | $431 | $5 |
| Acyclovir | 23 | $425 | $18 |
| Atorvastatin | 27 | $424 | $16 |
| Amlodipine Besylate | 30 | $255 | $8 |
| Doxazosin Mesylate | 12 | $229 | $19 |
| Gemfibrozil | 13 | $183 | $14 |
| Levothyroxine | 16 | $164 | $10 |
| Omeprazole | 12 | $137 | $11 |
| Atenolol | 30 | $135 | $4 |
| Metformin | 16 | $120 | $8 |
| Glyburide-Metformin | 13 | $117 | $9 |
| Zolpidem | 15 | $107 | $7 |
| Warfarin | 24 | $103 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $99 | $9 |
| Allopurinol | 17 | $89 | $5 |
| Hydroxyzine | 11 | $56 | $5 |
2013: 30 drugs
| Isentress | 123 | $163,172 | $1,327 |
| Truvada | 84 | $104,765 | $1,247 |
| Reyataz | 69 | $87,520 | $1,268 |
| Prezista | 19 | $34,956 | $1,840 |
| Norvir | 82 | $29,782 | $363 |
| Viramune Xr | 32 | $23,646 | $739 |
| Atripla | 12 | $22,569 | $1,881 |
| Intelence | 15 | $18,190 | $1,213 |
| Lamivudine | 26 | $17,116 | $658 |
| Selzentry | 12 | $12,967 | $1,081 |
| Androgel | 30 | $12,083 | $403 |
| Testim | 11 | $7,243 | $658 |
| Valacyclovir | 17 | $4,534 | $267 |
| Pradaxa | 12 | $3,168 | $264 |
| Doxycycline Monohydrate | 14 | $981 | $70 |
| Atorvastatin | 21 | $653 | $31 |
| Lisinopril | 78 | $463 | $6 |
| Acyclovir | 25 | $451 | $18 |
| Fluoxetine | 13 | $433 | $33 |
| Lamotrigine | 14 | $255 | $18 |
| Amlodipine Besylate | 26 | $250 | $10 |
| Zolpidem | 26 | $204 | $8 |
| Glyburide-Metformin | 11 | $171 | $16 |
| Gemfibrozil | 11 | $161 | $15 |
| Atenolol | 26 | $145 | $6 |
| Doxazosin Mesylate | 13 | $138 | $11 |
| Levothyroxine | 16 | $137 | $9 |
| Terazosin | 12 | $127 | $11 |
| Warfarin | 24 | $119 | $5 |
| Metformin | 12 | $95 | $8 |
Money from drug and device companies
$52 in 2025
| 2025 | 1 | 2 | None | $52 |
| 2024 | 1 | 2 | None | $41 |
| 2023 | 1 | 2 | $3,000 | $3,061 |
| 2022 | 2 | 9 | None | $873 |
| 2021 | 1 | 4 | $6,360 | $6,360 |
| 2020 | 1 | 3 | $11,040 | $11,040 |
| 2019 | 2 | 43 | $25,620 | $30,202 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ViiV Healthcare | Cabenuva | $52 | 2 payments
|
See all 2 published payments
| ViiV Healthcare | Meals · 2025-10-16 | Cabenuva | $24 |
| ViiV Healthcare | Meals · 2025-09-09 | Cabenuva | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $41
| ViiV Healthcare | Cabenuva | $41 | 2 payments
|
2023: $3,061
| ViiV Healthcare | None | $3,061 | 2 payments
|
2022: $873
| ViiV Healthcare | Cabenuva | $860 | 8 payments
|
| Janssen Biotech | Symtuza | $13 | 1 payment
|
2021: $6,360
| ViiV Healthcare | Cabenuva | $6,360 | 4 payments
|
2020: $11,040
| ViiV Healthcare | Dovato | $11,040 | 3 payments
|
2019: $30,202
| Merck Sharp & Dohme | Isentress | $15,294 | 20 payments
|
| ViiV Healthcare | None | $14,908 | 23 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2020 | Their institution | $313,150 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2019 | Their institution | $255,224 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2021 | Their institution | $226,223 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2022 | Their institution | $138,538 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2023 | Their institution | $47,856 |
| ViiV Healthcare Company · Ph 3 Hiv Two-Year Non-Inferiority Compared To Standard of Care Safety/ · 2019 | Their institution | $40,204 |
| ViiV Healthcare Company · A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2019 | Their institution | $28,698 |
| Janssen Research & Development, LLC · A Phase 3, Randomized, Active-Controlled, Open-Label Study To Evaluate the Efficacy, Safety and Tolerability of Switching To A Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-Daily Single-Tablet Regimen Versus Continuing the Current Regimen Consisting of A Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-Suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects · 2019 | Their institution | $4,809 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro · 2021 | Their institution | $3,000 |
| ViiV Healthcare Company · A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority · 2024 | Their institution | $1,020 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1689667495
- Licence
- CA 31728California A31728: Cancelled
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 3400 Data Dr, Rancho Cordova, CA, 95670
- NPI first listed
- 2005-08-26
- NPI last updated
- 2023-09-08
- NPI record certified
- 2023-09-08
This is when the NPI record was last certified, not a medical board exam.